5th PPRI Conference - Programme

Day 1: Thursday, 25 April 2024 (09:00-17:30)

09.00-09.45: Welcome

  • Federal Minister of Social Affairs, Health, Care and Consumer Protection Johannes Rauch 
  • Executive Director Herwig Ostermann, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute) 
  • WHO Representative Klara Tisocki, Team Lead Health Technology Access Management team (AMP), Department of Innovation and Emerging Technologies (IET), Medicines and Health Products, World Health Organization Geneva
  • European Commission (DG SANTE) representative, Rainer Becker, Director SANTE D – Medical Products and Innovation (video message)
  • Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Sabine Vogler (GÖG / Austrian National Public Health Institute)

Facilitator: Nina Zimmermann, GÖG / Austrian National Public Health Institute

9.45-10.30: Keynote presentation: How to make medicines more accessible and affordable - From evidence to policy to practice 

Meindert Boysen, Independent Consultant and Chair of Health Technology Assessment international (HTAi) Global Policy Forum, UK

Download presentation

Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute

10.30-11.00: Coffee Break 

11.00-12.15: Stakeholder Debate: Ensuring access to affordable medicines through innovative policies?

  • Johan Ponten, Dental and Pharmaceutical Benefits Agency (TLV), Sweden
  • Thomas Allvin, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Maja Graf, International Generic and Biosimilar Medicines Association (IGBA) 
  • Giulia Segafredo, Medicines Patent Pool
  • Anca Toma, European Patients Forum

Facilitator: Dimitra Panteli, European Observatory on Health Systems and Policies, Belgium

12.15–12.30: Outlook on Conference 

Nina Zimmermann, GÖG / Austrian National Public Health Institute

12.30-14.00: Lunch Break

14.00-14:20: Keynote presentation: Can people afford to pay for health care? Evidence on financial protection in 40 countries in Europe

Tamás Evetovits, WHO Barcelona Office for Health Systems Financing, Division of Country Health Policies and Systems 

Download presentation

Facilitator: Nina Zimmermann, GÖG / Austrian National Public Health Institute

14.30–15.30: Breakout Session (Strand I – Strand III)

Strand I: Local challenges, global learnings?

Keynote presentation: Competition enforcement in the pharmaceutical sector - European competition authorities working together for affordable and innovative medicines download presentation

Leen De Vreese, European Commission, DG Competition, Belgium 

  • Are competition fines effective deterrents to excessive pricing of medicines? Evidence from a landmark competition case in the United Kingdom download presentation
    Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), USA
  • Assessing medicines access time: a cross-country comparison in Europe download presentation
    Sophie Delcroix-Lopes & Nadia Amer, National Health Insurance (CNAM), France

Facilitator: Veronika Wirtz, WHO Collaborating Center in Pharmaceutical Policy, Boston University School of Public Health, USA

Strand II: Strengthening the evidence base

Keynote presentation: Update from the WHO Fair Pricing Forum download presentation
Klara Tisocki, WHO Geneva, Switzerland

  • Savings and Transparency: Comparing Publicly Reported Data on Managed Entry Agreements in Europe 
    Nora Franzen, Netherlands Cancer Institute, The Netherlands
  • Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies download presentation 
    Vittoria Ardito, Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Italy 

Facilitator: Aukje Mantel-Teeuwisse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Netherlands

Strand III: Futureproofing pharmaceutical policies

Keynote presentation: Use of strategic approaches in public procurement of medicines: improving affordable patient access to medicines and protecting the environment in 32 European countries download presentation

Maximilian Salcher-Konrad, GÖG / Austrian National Public Health Institute

  • Tendering of medically equivalent, patented outpatient pharmaceuticals download presentation
    Hallstein Husbyn, Norwegian Medical Products Agency, Norway
  • First Nordic Tender with Environmental Criteria download presentation
    Rasmus Syberg Hazelton, Amgros I/S, Denmark

Facilitator: Jaime Espin Balbino, Andalusian School of Public Health, Granada, Spain

15.30–16.00: Poster walk during the coffee break

16.00 –16.45: Moderated poster session

Strand I: Local challenges, global learnings?

  • Early and compassionate access to medicines in France: two years after launch, what did and did not work? download poster
    Newfel Chekroun & Mayeul Charoy, Direction de la sécurité sociale, France
  • Selection of novel medicines for acute conditions versus chronic conditions on National Essential Medicines Lists compared to the WHO Model List download poster
    Moska Hellamand, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
  • Bridging perspectives: identification of best practices for public and patient involvement in pharmaceutical pricing and reimbursement policies – a comprehensive study download poster
    Lourdes Cantarero Arevalo, WHO Collaborating Centre in Patient Perspective on Medicine Use, Department of Pharmacy, University of Copenhagen, Denmark

Facilitator: Friederike Windisch, GÖG / Austrian National Public Health Institute

Strand II: Strengthening the evidence base

  • Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’ download poster
    Nicole Grössmann-Waniek, HTA Austria - Austrian Institute for Health Technology Assessment GmbH, Austria
  • Needs Examination, Evaluation and Dissemination (NEED): Towards a needs assessment framework and evidence database to support needs-driven innovation and policy in healthcare download poster
    Muriel Levy, Belgian Health Care Knowledge Centre (KCE), Belgium
  • How to Price Advanced Therapies? Mixed approach for valuing a new CAR-T Cell for Multiple Myeloma in Brazil download poster
    Augusto Guerra, Collaborating Centre for Health Technology Assessment and Excellence (CCATES) / Postgraduate Program in Medicines and Pharmaceutical Assistance at the Federal University of Minas Gerais (PPGMAF/UFMG), Belo Horizonte, Brazil

Facilitator: Margit Gombocz, GÖG / Austrian National Public Health Institute

Strand III: Futureproofing pharmaceutical policies

  • Break on through (to the other side). A case study on increasing access to affordable CAR-T therapy through an academic hospital’s alternative innovation model download poster
    Adrian Alonso Ruiz, Global Health Centre, Graduate Institute of Development and International Studies, Switzerland
  • Cost analysis of TB-PRACTECAL, a multicentre phase 2/3 trial in drug-resistant TB download poster
    Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), USA
  • Using futures methods to think through financing for medicines R&D and issues of access download poster
    Sarah Parkinson, RAND Europe, UK

Facilitator: Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, South Africa

16.45-17.30: Reception

 

Day 2: Friday 26 April 2024 (09:00 - 16:00)

08.00-08.45: Early Bird Session: Meet the Editors

  • Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar download presentation
  • International Journal of Technology Assessment in Health Care, Claudia Wild download presentation
  • Health Policy Journal, Nathan Shuftan download presentation
  • Adis HEOR Journals (Applied Health Economics and Health Policy, Pharmacoeconomics, Pharmacoeconomics - Open), Tim Wrightson (video message)

Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute

9.00-09.30: Keynote presentation: WHO and Access to medicines - an update 

Natasha Azzopardi Muscat, WHO Regional Office for Europe, Denmark (video message)
Tarang Sharma, WHO Regional Office for Europe, Denmark (online) download presentation

Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute

9.30-10.30: Country poster presentations

European Union

  • Croatia (Eva Šintić, Agency for Medicinal Products and Medical Devices of Croatia, Halmed and Martina Kavur Majer, Croatian Health Insurance Fund) download poster
  • Denmark (Diana Ina Lauritzen, Danish Medicines Agency and Rasmus Syberg Hazelton, Amgros I/S) download presentation
  • France (Mayeul Charoy, Direction de la sécurité sociale and Clement Huiban, CEPS, France) download poster

Facilitator: François Janssens, European Commission DG SANTE

Other European Countries

  • Norway (Carolin Hagen, Norwegian Ministry of Health and Care Services) download poster
  • Türkiye (Irem Karaomerlioglu, Turkish Medicines and Medical Devices Agency) download poster
  • Ukraine (Oresta Piniazhko, State Expert Centre of Ministry of Health of Ukraine and Svitlana Pakhnutova, WHO Country Office Ukraine) download presentation

Facilitator: Iuliana Garam, WHO Country Office Moldova 

Non-European Countries

  • Brazil (Luciene Fontes Schluckebier Bonan, Brazilian Ministry of Health and Fernando Rego, ANVISA) download poster
  • Singapore (Ivan Koh, Agency for Care Effectiveness (ACE), Ministry of Health) download poster
  • South Africa (Andy Gray and Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal) download presentation

Facilitator: Veronika Wirtz, WHO Collaborating Center in Pharmaceutical Policy, 
Boston University School of Public Health, USA

10.30–11.00: Country Poster walk during the coffee break

11.00–12.30: Breakout Session (Strand I – III)

Strand I: Local challenges, global learnings?

Keynote presentation: Conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs) download presentation
Zaheer-Ud-Din Babar, Professor in Medicines and Healthcare, University of Huddersfield, UK

  • Finland as a trailblazer in the uptake of less expensive biologic medicines – measures introduced in 2023 and 2024 download presentation
    Kati Sarnola, Research at Kela, Social Insurance Institution of Finland (Kela), Finland
  • Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa download presentation
    Iris Joosse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands
  • Human normal immunoglobulin in Portugal: Analysing price increases across multiple markets download presentation
    Ana Correia, INFARMED – National Authority of Medicines and Health Products, I.P., Portugal

Facilitator: Aukje Mantel-Teeuwisse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Netherlands

Strand II: Strengthening the evidence base

Keynote presentation: The role of transparency and evidence in improving access to medicines download presentation
Dimitra Panteli, European Observatory on Health Systems and Policies, Belgium

  • The desirability of implementing an outcome-based delayed payment model for autologous gene therapy atidarsagene autotemcel (Libmeldy®) download presentation
    Marcelien Callenbach, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands
  • European comparison of prices for off-patent medicines – findings for 16 countries and implications for methodological choices download presentation
    Peter Schneider, GÖG / Austrian National Public Health Institute

Facilitator: Jaime Espin Balbino, Andalusian School of Public Health, Granada, Spain

Strand III: Futureproofing pharmaceutical policies

Keynote presentation: OECD’s quest for transparency in pharma markets - an update on recent contributions download presentation
Eliana Barrenho, OECD, France

  • Using AIM’s Fair Pricing Calculator for affordable and evidence-based pricing decisions, transitioning from policy concept to (inter-) national testing download presentation
    Thomas Kanga-Tona, International Association of Mutual Benefit Societies (AIM), Belgium
  • Disaggregation Of The Costs Of Pharmaceutical Research And Development download presentation
    Daniel Fabian, HTA Austria - Austrian Institute of Health Technology Assessment GmbH, Austria
  • Unlocking global access to medicines for pandemics: the potential and limits of alternative innovation models download presentation
    Iulia Slovenski, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland

Facilitator: Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, South Africa

12.30–13.30: Lunch

13.30-15.00: Workshops

  • Access to new and expensive medicines in Austria: what role for the new "appraisal board"?
    A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, GÖG (Austrian National Public Health Institute) download presentation
    Facilitator: Maximilian Salcher-Konrad (GÖG / Austrian National Public Health Institute)
    • Presentation of the Austrian pharmaceutical system (Sabine Vogler, GÖG / Austrian National Public Health Institute)
    • Panel discussion on "Key challenges for affordable access to new medicines: what role for a new process for assessing selected new and expensive medicines in Austria?"
      • Sarah Mörtenhuber (Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection)
      • Claas Röhl (patient representative: NF Kinder)
      • Nathanael Paterno (hospital payer: WIGEV / Vienna Healthcare Group)
      • Ronald Pichler (pharmaceutical industry: PHARMIG)
      • Invited commentary: Carolin Hagen (Norwegian Ministry of Health and Care Services)
  • How the Euripid collaboration contributes to improving access to biosimilars 
    A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, GÖG (Austrian National Public Health Institute) and the EURIPID collaboration download presentation
    Facilitator: Claudia Habl (GÖG / Austrian National Public Health Institute, Secretary of the Board of Participants (BoP) of EURIPID)
    • Introduction of EURIPID and current EC Grant (Gergely Németh, Semmelweis University, Hungarian National Health Insurance Fund, project manger of EURIPID)
    • Impact of market entries of biosimilars in Slovenia (Matjaž Marc, Agency for Medicinal Products and Medical Devices of the Slovenian Republic (JAZMP))
    • Panel discussion on „Biosimilars – Monitoring & policies in the product life cycle management“ 
      • Francis Arickx (National Institute for Health and Disability Insurance (RIZIV-INAMI), Belgium) [online]
      • Liese Barbier (Katholieke Universiteit Leuven, Belgium, European Medicines Agency (EMA))
      • Dorthe Barthels (AMGROS I/S, Denmark)
      • Frode Hellesnes (Biogen, Sweden)
  • Cross-border HTA partnerships and their role in sustainable access to medicines 
    A workshop organised by the Deloitte Health Economics and Outcomes Research Team Brussels download presentation
    Facilitator: Burcak Aydin, Health Economics and Outcomes Research Team Brussels Deloitte 
    • Presentation on the cross-border HTA collaborations including methodology development, information sharing during an appraisal and a joint production of REAs
    • Panel discussion on recent case studies where the cross-border HTA collaboration served to improve sustainable access to medicines (eg. reduction in appraisal timelines, higher quality appraisals) and what needs to be done more in the near future 
      • Dalia Dawoud (Associate Director, Science, Policy and Research Programme, National Institute for Health and Care Excellence (NICE), UK)
      • Matteo Scarabelli (Associate Director, Market Access, EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium)
      • Anja Schiel (Senior Advisor, Norwegian Medical Products Agency, Norway)
      • Anca Toma (Executive Director, European Patients' Forum, Belgium)

15.00-15.45: Keynote presentation: Action needed: Rediscovering Solidarity in Europe and beyond

Anja Schiel, Senior Advisor, Norwegian Medical Products Agency, Norway download presentation

Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute

15.45-16.00: Conclusions, awards and closure

Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG / Austrian National Public Health Institute